Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

The hypomethylating agents (HMAs) are standard therapy for patients with higher-risk myelodysplastic syndrome (MDS); however, the majority of the patients will lose their response to HMAs over time due to unknown mechanisms. It has recently been shown that T cell expression of the immunoinhibitory r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ørskov, Andreas D., Treppendahl, Marianne B., Skovbo, Anni, Holm, Mette S., Friis, Lone S., Hokland, Marianne, Grønbæk, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496243/
https://www.ncbi.nlm.nih.gov/pubmed/25823822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496243/
https://www.ncbi.nlm.nih.gov/pubmed/25823822

Ejemplares similares